To characterize efficacy signals and safety profiles of immune checkpoint inhibitors (ICIs) in pediatric CNS tumors and identify specific biomarkers of response.
Key Findings:
Pediatric CNS tumors are biologically heterogeneous, affecting the efficacy of ICIs.
Certain tumor types, like replication-repair–deficient tumors, show promise for checkpoint blockade due to hypermutation.
Medulloblastoma often lacks immune activity, explaining limited success of ICI monotherapy.
Emerging combination strategies are being explored to enhance immune responses.
Challenges in ICI use in pediatric populations include lower TMB and unique immune landscapes.
Interpretation:
The review highlights the potential for ICIs in specific pediatric brain tumor subtypes, particularly those with high mutation rates, while also acknowledging the challenges posed by the unique immune landscape of pediatric CNS tumors and the need for tailored approaches.
Limitations:
Fragmented evidence due to the rarity and biological diversity of pediatric CNS tumors.
Logistical challenges in conducting prospective studies in children.
Potential biases in study selection and reporting.
Conclusion:
Further research is needed to optimize ICI use in pediatric brain tumors, particularly through biomarker-driven approaches and combination therapies, focusing on specific tumor types and immune profiles.
by Yaxel Levin-Carrion, Jayant Bhasin, Kevin Titkov, Sraavya Anne, Arman Sawhney, Caryn J. Ha, Ibraheem Sharaf, Marvens Jean, Jacob Santana, Drew Thibault, Alejandro Pando, Nemanja Novakovic, Nehal S. Parikh, Morana Vojnic, Jonathan H. Sherman
The Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, part of Baptist Health, reached an important milestone in the advancement of cancer care with the successful treatment of its first patient utilizing proton therapy, according to physicians at both the Institute and the hospital.
Offering sigmoidoscopy screening led to reduced incidence of colorectal cancer, though more for men vs women, and a reduced rate of colorectal cancer–related mortality in men, according to findings fr...
In a systematic review and meta-analysis reported in JAMA Oncology, Miszczyk et al found that local therapies alone are associated with “reasonable efficacy” in select patients with locally radiorecur...
